Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer

BACKGROUND: This trial evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple–negative breast cancer (mTNBC). METHODS: Eligibility criteria were mTNBC, RECIST 1.1 measurable disease, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yuan, Yost, Susan E, Cui, Yujie, Ruel, Christopher, Murga, Mireya, Tang, Aileen, Martinez, Norma, Schmolze, Daniel, Waisman, James, Patel, Niki, Vora, Lalit, Tumyan, Lusine, Bozoghlanian, Mari, Stewart, Daphne, Frankel, Paul H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322142/
https://www.ncbi.nlm.nih.gov/pubmed/37023705
http://dx.doi.org/10.1093/oncolo/oyad026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322142/
https://www.ncbi.nlm.nih.gov/pubmed/37023705
http://dx.doi.org/10.1093/oncolo/oyad026

Ejemplares similares